Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2009

View Archived Issues

Sanofi-aventis scientists describe new anticancer Hsp90 inhibitors in recent patent

GSK claims novel PI3Kalpha inhibitors with potential as anticancer agents

BMS scientists report new dual-action NK-1 antagonists/5-HT reuptake inhibitors

New P2Y12 receptor antagonists claimed by sanofi-aventis for thrombotic disorders

Kyowa Hakko Kirin reports prostanoid FP receptor agonists with antiglaucoma properties

New histamine H3 receptor antagonists for treatment of AD reported by Wyeth

Novel neuraminidase inhibitors for treating influenza prepared at Hokkaido University

PanThera divulges new anthrax lethal factor inhibitors

Target candidate: CTGF/CCN2, a protective factor in pancreatic tumor cells

Biopartners appeal the CHMP's negative opinion on Biferonex

Endocyte begins phase II EC-145 trial for ovarian cancer

FDA issues public health advisory for Raptiva, EMEA recommends suspension

European Commission approves Firmagon for prostate cancer

EMEA recommends continued vaccination with Gardasil

CV Therapeutics rejects Astellas Pharma's unsolicited proposal

Astellas Pharma offers third quarter summary

Shire acquires worldwide rights to Equasym IR/XL from UCB

QRxPharma initiates comparative study of MoxDuo in knee replacement surgery

Schering-Plough submits response to FDA complete response letter for Saphris NDA

BioInvent and ThromboGenics commence phase II trial of TB-402

UCB presents outcomes for proof-of-concept lacosamide and rotigotine studies

Encouraging results support further development of Almirall's LAS-100977

Acrux reports positive data for contraceptive skin spray trials